EU approval for GSK's Incruse as Anoro waits in wings
This article was originally published in Scrip
Executive Summary
The European Commission has approved GlaxoSmithKline's once-daily, maintenance bronchodilator treatment Incruse (umeclidinium 55mcg) to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD), following a recommendation by the CHMP in February (scripintelligence.com, 21 February 2014).